Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$821K Buy
3,262
+1,172
+56% +$252K 0.08% 158
2026
Q1
$455K Buy
2,090
+423
+25% +$93.8K 0.05% 188
2025
Q4
$381K Buy
1,667
+14
+0.8% +$3.19K 0.05% 195
2025
Q3
$383K Sell
1,653
-81
-5% -$16.5K 0.05% 185
2025
Q2
$322K Sell
1,734
-29
-2% -$5.39K 0.05% 185
2025
Q1
$369K Sell
1,763
-4
-0.2% -$778 0.06% 157
2024
Q4
$314K Sell
1,767
-73
-4% -$13.4K 0.05% 173
2024
Q3
$363K Sell
1,840
-47
-2% -$8.77K 0.07% 156
2024
Q2
$324K Sell
1,887
-9,617
-84% -$1.59M 0.06% 162
2024
Q1
$2.09M Buy
11,504
+9,574
+496% +$1.65M 0.47% 55
2023
Q4
$299K Buy
1,930
+20
+1% +$2.92K 0.06% 159
2023
Q3
$285K Sell
1,910
-590
-24% -$86.6K 0.07% 152
2023
Q2
$337K Buy
2,500
+1
+0% +$147 0.08% 141
2023
Q1
$398K Buy
2,499
+173
+7% +$26.4K 0.1% 126
2022
Q4
$376K Buy
2,326
+290
+14% +$44.5K 0.11% 116
2022
Q3
$273K Buy
+2,036
New +$292K 0.14% 83

Other funds holding ABBV

Eagle Strategies's ABBV Position: Q2 2026 in Review

Eagle Strategies increased its AbbVie (ABBV) stake by 56% in Q2 2026, buying an estimated $252K and bringing the position to 3,262 shares worth $821K. The position accounts for 0.08% of the portfolio, ranked #158.

Eagle Strategies first reported a position in ABBV in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.09M in Q1 2024. 2,236 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Eagle Strategies held 3,262 shares of AbbVie worth $821K as of Q2 2026.
  • Eagle Strategies bought 1,172 AbbVie shares in Q2 2026, an estimated $252K.
  • AbbVie made up 0.08% of Eagle Strategies's portfolio in Q2 2026, its #158 holding.
  • Eagle Strategies first reported a position in AbbVie in Q3 2022 and has held it in 16 quarters since.
  • Eagle Strategies's AbbVie position peaked at $2.09M in Q1 2024.
  • 2,236 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Eagle Strategies's 13F filing for Q2 2026, filed 21 Jul 2026.